Supports innovation and provide access to novel antibacterial drugs against biothreats
Cipla Therapeutics, an affiliate of Cipla and SIGA Technologies, a commercial-stage pharmaceutical company focusing on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats.
“The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a US Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs,” said Garrett Ingram, CEO, Cipla Therapeutics and added “AMR is a global priority for Cipla and our continued investment in this area along with SIGA’s drug development and US experience creates a unique and strong partnership.”
“We are thrilled to have teamed up with Cipla to tackle the very important public health challenge of AMR,” said Phil Gomez, CEO, SIGA. “Our longtime partner BARDA has recognised this as a critical issue, for not only public health but biothreats as well. With our drug development expertise under the animal rule and government contracting expertise, and Cipla’s novel antibiotic products and extensive manufacturing capabilities, we are confident that together we are ideally suited to provide innovative solutions to BARDA and other government customers.”
SIGA has secured and successfully managed multiple contracts awarded by the US government over a period of more than 10 years that provide for the development and procurement of up to approximately $1 billion for the supply and re-supply of TPOXX in the Strategic National Stockpile. In addition, SIGA brings expertise in developing and improving US-based supply chains to enable the robust delivery of medical countermeasures to the US Government.
The partnership provides an opportunity for US Government agencies such as BARDA to advance preparation and health security programme initiatives with the novel antibiotic ZEMDRI while working through a known partner in SIGA, an entity with deep expertise in USG contracting and BARDA’s hands-on approach to advanced development.
